Related Experiment Video

Updated: Jan 10, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K

A CD206 targeting peptide exhibits preclinical therapeutic efficacy in cutaneous T-cell lymphoma

Rishob Dasgupta1, Pyung Hun Park2, Molly Wallace1

  • 1Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

The Journal of Investigative Dermatology
|November 28, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
CTCLImmune modulationMacrophage phenotypeTumor microenvironment

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.2K

Related Experiment Videos

Last Updated: Jan 10, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

Articles linked to this work by shared authors, journal, and citation graph.

ATP-dependent chromatin remodelers in prostate cancer progression and therapeutic resistance.

Endocrinology·2026

Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.

Case reports in dermatological medicine·2026

Do Prophylactic Antibiotics Decrease Risk of Infection in Closed Percutaneous Pinning of Pediatric Hand Fractures?

Journal of pediatric orthopedics·2026

Trainee and Faculty Perspectives on Global Oncology: Assessing Interest, Barriers, and Opportunities.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026

Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens.

Microbiology (Reading, England)·2026

Human LFA-1 governs T cell immune surveillance of the skin.

Science immunology·2026

DNPH1 exerts context-dependent tumor-promoting and -repressing functions during melanoma development.

The Journal of investigative dermatology·2026

Skin Cancer Risk Stratification and Outcomes in Swedish Solid Organ Transplant Recipients.

The Journal of investigative dermatology·2026

Proteomic signature predicts the metastatic risk of primary cutaneous squamous cell carcinomas.

The Journal of investigative dermatology·2026

The AhR-TFAP2A Axis Regulates Melanosome Transport by Directly Targeting Myosin Va and Mlph.

The Journal of investigative dermatology·2026

Differential BET protein recruitment to IL6 and IL8 promoters and suppression of inflammatory and cell cycle genes by BET inhibitor in keratinocytes.

The Journal of investigative dermatology·2026

Lesional hair lipidomic signatures reveal ARA-LTB4 pathway activation and NETs formation in hidradenitis suppurativa.

The Journal of investigative dermatology·2026

Long-Term Efficacy and Allograft Loss after Immune Checkpoint Inhibitor Therapy in Solid Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma.

medRxiv : the preprint server for health sciences·2026

Engineered subtilisin protease degrades active KRAS in cancer cells leading to differential cell targeting.

Research square·2026

Microenvironment-derived acetylated amino acids promote glioblastoma treatment resistance.

Research square·2026

The therapy-conditioned host: a state-transition framework for second primary cancer evolution.

Frontiers in oncology·2026

Cyclopeptide 161 protects human dermal fibroblasts against UV-induced damage via the MEK1/2-ERK1/2 signaling pathway.

Frontiers in physiology·2026

Dynamic clonal evolution of multiple bypass resistance mechanisms in EGFR-mutant lung adenocarcinoma: a case report.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us